Diagnosis and Treatment of Therapy-related Acute Myeloid Leukemia.

@article{Strickland2022DiagnosisAT,
  title={Diagnosis and Treatment of Therapy-related Acute Myeloid Leukemia.},
  author={Stephen A. Strickland and Norbert Vey},
  journal={Critical reviews in oncology/hematology},
  year={2022},
  pages={
          103607
        }
}
  • S. StricklandN. Vey
  • Published 1 January 2022
  • Medicine, Biology
  • Critical reviews in oncology/hematology

The Role of Immune Checkpoint Blockade in Acute Myeloid Leukemia

CTLA-4 blockage was a worthy therapeutic approach in relapsed hematologic malignancies, presenting long-lasting responses in AML patients, and therefore AML treatment.

Pathogenic Mechanisms in Acute Myeloid Leukemia

Improving understanding of the molecular mechanisms that lead to acute myeloid leukemia will provide novel opportunities to treat AML as well as prevent the development of disease.

The stem cell-specific long non-coding RNAs in leukemia.

  • M. FarzanehSajad Najafi S. Azizidoost
  • Biology
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • 2022
Current knowledge concerning lncRNAs' implication in the pathogenesis of LSCs is reviewed and their prognostic, diagnostic, and therapeutic potential are discussed.

References

SHOWING 1-10 OF 70 REFERENCES

Therapy-related myeloid leukemia.

A deeper understanding of the factors that predispose patients to the development of therapy-related myeloid leukemia would help clinicians monitor patients more carefully after treatment for a primary condition and could influence initial treatment strategies with the goal of decreasing the incidence of this serious complication.

Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype

Death in remission is the main driver of inferior outcome in t-AML, and careful therapeutic decisions are required to mitigate potential treatment-related toxicity in this rare subgroup of patients with newly diagnosed AML and normal karyotype.

The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML.

In more intensively treated younger adults, treatment-related toxicity had a major negative impact on outcome, possibly reflecting cumulative toxicity of cancer treatment.

‘Acute myeloid leukemia: a comprehensive review and 2016 update'

The identification of recurrent genetic mutations, such as FLT3-ITD, NMP1 and CEBPA, has helped refine individual prognosis and guide management and here, the major recent advances in the treatment of AML are reviewed.

Therapy-related leukemia and myelodysplasia: susceptibility and incidence

Among patients with hematologic malignancies, long-term survivors of Hodgkin’s lymphoma are exposed to an increased risk of t-MDS/AML, particularly when receiving MOPP-based, and escalated BEACOPP regimens, and when alkylators are combined with radiotherapy.

Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?

  • M. Heuser
  • Medicine, Biology
    Hematology. American Society of Hematology. Education Program
  • 2016
The prognostic impact of currently known risk factors and the therapeutic options in different patient subgroups will be discussed.

Therapy-related myelodysplasia and acute myeloid leukemia.

  • S. Bhatia
  • Medicine, Biology
    Seminars in oncology
  • 2013
Inter-individual variability in the risk for development of t-MDS/AML suggests a role for genetic variation in susceptibility to genotoxic exposures.

Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.

The results support that de novo AML, sAML, and tAML are biologically and prognostically distinct subtypes of AML and should be integrated in treatment recommendations for these patients.

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.

Analysis of serial samples from individual patients revealed that the presence of a mutation in SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, or STAG2 was >95% specific for the diagnosis of s-AML and highlights a subset of patients with worse clinical outcomes, including a lower complete remission rate, more frequent reinduction, and decreased event-free survival.

Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML

Data indicate that cytogenetics are an important prognostic parameter in t-AML and de novo AML is an unfavorable factor independent of cytogenetic factors with respect to survival.
...